Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
Author:
- The EMPA-KIDNEY Collaborative GroupTGThe EMPA-KIDNEY Collaborative Group
Top Cited Papers
Open Access
- 20 February 2025
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (8) , 777-787
Abstract
Empagliflozin exerted positive cardiorenal effects in the EMPA-KIDNEY trial; this study reports active trial plus post-trial data. In this trial, patients with an estimated glomerular filtration rate 20-2 and urinary albumin-to-creatinine ratio of ≥200mg/g received either empagliflozin 10mg daily or matching placebo for two years (median). Subsequently, surviving participants who consented were observed post-trial for two additional years. No study drug was issued in the post-trial period, but local doctors could prescribe SGLT2 inhibitors. The primary composite outcome was kidney disease progression or cardiovascular death assessed from the start of the active trial to the end of the post-trial period. 4891 of 6609 randomized participants (74%) entered the post-trial period, during which, SGLT2 inhibitor use was similar between groups (empagliflozin group 43% vs. placebo 40%). Over the entirety of follow-up (study initiation to post-trial observation end) a primary outcome occurred in 865/3304 (26.2%) of the empagliflozin group and 1001/3305 (30.3%) of the placebo group (HR=0.79, 95%CI 0.72-0.87). There was a 13% (0.87, 0.76-0.99) reduction in risk of the primary outcome during the post-trial period in the empagliflozin group. Compared with placebo, original allocation to empagliflozin reduced risk of kidney disease progression (23.5%vs.27.1%), the composite of death or end-stage kidney disease (16.9%vs.19.6%), and cardiovascular death (3.8%vs.4.9%). There was no effect on non-cardiovascular death (5.3%vs.5.3%). In a broad range of patients with chronic kidney disease, empagliflozin continued to exert additional cardiorenal benefits for up to 12 months after it was discontinued. (Funding: Boehringer Ingelheim & others. Trial registration numbers: Clinicaltrials.gov: NCT03594110; EuDRACT: 2017-002971-24.)Keywords
Funding Information
- NIHR Oxford Biomedical Research Centre
- Eli Lilly and Company
- Boehringer Ingelheim
- Health Data Research UK
- Medical Research Council (MC_UU_00017/3)
- British Heart Foundation
This publication has 17 references indexed in Scilit:
- Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEYClinical and Experimental Nephrology, 2024
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trialThe Lancet Diabetes & Endocrinology, 2023
- Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trialThe Lancet Diabetes & Endocrinology, 2023
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsThe Lancet, 2022
- Glomerular hyperfiltrationNature Reviews Nephrology, 2022
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- Chronic Kidney DiseaseThe Lancet, 2017
- Empagliflozin and Progression of Kidney Disease in Type 2 DiabetesNew England Journal of Medicine, 2016
- Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysisThe Lancet, 2012